Polycyclic Heterocycle Free Base Crystal Form for Selective OX2R Antagonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current orexin receptor antagonists targeting both OX1R and OX2R receptors cause side effects like increased sleepiness and cannot effectively treat depression due to their impact on rapid eye movement sleep, while selective OX2R antagonists are limited in clinical availability.
Innovation Solution
Development of a crystal form of a polycyclic nitrogen-containing heterocycle compound with specific structural characteristics, represented by general formula (I), which acts as a selective OX2R antagonist, providing a stable and easy-to-handle form for pharmaceutical applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dual OX1R/OX2R antagonists are used, then insomnia treatment efficacy is improved, but side effects like sleepiness increase and antidepressant effect is lost
Solution Approach 1:
The patent segments the dual receptor antagonism function into separate selective OX2R antagonist components. The compound selectively targets OX2R receptors while avoiding OX1R receptors, thereby maintaining insomnia treatment efficacy without causing the sleepiness side effects associated with OX1R antagonism. This selective targeting approach divides the therapeutic action from the harmful side effects.
2Reliability
If dual OX1R/OX2R antagonists are used, then insomnia treatment is enhanced, but antidepressant effect cannot be achieved
Solution Approach 1:
The patent segments the therapeutic indications by selectively targeting only OX2R receptors. This selectivity enables the compound to treat insomnia while preserving the natural physiological functions mediated by OX1R receptors, thereby maintaining antidepressant effects that are disrupted by dual antagonists.
3Object-affected harmful factors
If selective OX2R antagonists are developed, then side effects are reduced and antidepressant effect is maintained, but clinical availability is limited
Solution Approach 1:
The patent employs parameter changes in the molecular structure of the compound to achieve selective OX2R antagonism. By modifying structural parameters such as the polycyclic nitrogen-containing heterocycle core and substituent groups, the compound achieves high selectivity for OX2R receptors, thereby reducing side effects and enabling broader clinical applicability.
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention relates to a free base crystal form of a polycyclic compound of a nitrogen-containing heterocycle, and a preparation method therefor. Specifically, the present invention provides a free base crystal form of a compound having general formula (I), a preparation method therefor, a pharmaceutical composition containing a therapeutically-effective amount of the crystal form, and a use thereof as an orexin receptor antagonist in the preparation of drugs for treating nervous system diseases.